logo

Viking Therapeutics, Inc. (VKTX)



Trade VKTX now with
  Date
  Headline
2/2/2018 8:35:46 AM Viking Therapeutics Prices Public Offering Of 11 Mln Shares At $5/Shr
11/28/2017 7:03:57 AM Viking Therapeutics Says Positive Top-Line Results From Phase 2 Study Of VK5211 For Recovering From Hip Fracture
10/24/2017 7:14:05 AM Viking Therapeutics Presents Results From In Vivo Study Of VK2809 In Biopsy
10/4/2017 7:08:29 AM Viking Says Positive Top-line Results From Proof-of-concept Study Of VK0214 In An In Vivo Model Of X-ALD
9/29/2017 7:06:11 AM Viking Announces Purchase Deals For Up To $16.25 Mln With Lincoln Park Capital
9/11/2017 7:09:59 AM Viking Therapeutics Announces Results Of Gene Expression Analysis From In Vivo Study Of VK2809 In NASH
7/12/2017 7:02:24 AM Viking Therapeutics Completes Enrollment In Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture
6/6/2017 7:15:34 AM Viking Therapeutics Announces Positive Top Line Results From In Vivo Study Of VK2809 In Non-Alcoholic Steatohepatitis
3/21/2017 4:06:43 PM Viking Therapeutics Q4 Loss/share $0.18 Vs. Loss $0.56 Year Ago
11/15/2016 7:13:09 AM Viking Therapeutics Presents New Clinical Data On VK2809 In Subjects With Elevated Cholesterol At AHA
10/4/2016 7:07:20 AM Viking Doses First Patient In Phase 2 Trial Of VK2809 For Hypercholesterolemia& Non-Alcoholic Fatty Liver Disease
9/26/2016 7:16:40 AM Viking Presents Positive Proof-of-Concept Data For VK0214 In In Vivo Model Of X-Linked Adrenoleukodystrophy
9/1/2016 7:31:38 AM Viking Presents Phase 1 Data And Highlights Ongoing Phase 2 Study Of VK5211